Biotech News

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Exelixis (EXEL)Exelixis2026-09-01 20:05 ESTConference / presentation

– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 1, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21 st Annual Healthcare

Related news

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST

Regeneron Announces Investor Conference Presentations

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

View all latest news

Exelixis

Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...

Recent company news

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

EXELExelixis2026-08-31 18:30 EST

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

Stock data

Close: 68.71 USD
Market cap: 12.2B USD
Exchange: NASDAQ
Sector: Small Molecule Drugs
Location: United States